Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 132

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 132
---
 segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, or decision-making group in making decisions on how to allocate resources and assess performance. Our CODM is our CEO. Our CEO views our operations and manages our business as one operating segment, which derives its revenues from the development and commercialization of therapies for patients with rare diseases.Our CEO manages and allocates resources to the operations of our company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, our CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on our consolidated net income (loss). Through this analysis, the CODM assesses performance by comparing actual consolidated net income (loss) versus the budget, and then decides how to allocate resources to invest in our research and development programs. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses:Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Product revenue, net$12,455 $8,615 $21,181 $16,804 PK activator (PYRUKYND®) direct expenses - research and development(29,809)(27,968)(51,130)(54,004)Compensation and related expenses - research and development(27,594)(27,476)(60,584)(55,110)Total selling, general and administrative expenses(45,869)(35,536)(87,396)(66,550)Other segment items*(21,203)(13,753)(23,380)(18,807)Net loss$(112,020)$(96,118)$(201,309)$(177,667)*Other segment items primarily include cost of sales, other research and development expenses and interest income.

12. Subsequent Events

On July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was enacted in the United States, which includes significant changes to federal tax law and other regulatory provisions that may impact the Company. We are currently evaluating the impact of the OBB